Prokidney Corp. ((PROK)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prokidney Corp. is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)’. The study aims to evaluate the safety and effectiveness of REACT injections in patients with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), which could significantly impact treatment options for these conditions.
The intervention being tested is the Renal Autologous Cell Therapy (REACT), a biological treatment involving injections into the kidneys. This therapy is designed to improve kidney function in patients with T2DM and CKD.
The study is a randomized, double-blind, multi-center trial with two cohorts. Participants are randomly assigned to either receive the REACT injections or undergo sham procedures. The primary goal is to assess the treatment’s effectiveness, with both participants and outcomes assessors blinded to the group assignments.
The study began on January 5, 2022, with an estimated completion date in 2025. The most recent update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence Prokidney Corp.’s stock performance by boosting investor confidence if the results are positive. It also places Prokidney in a competitive position within the biotech industry, particularly in the renal treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.